A Study of CM350 in Patients With Advanced Solid Tumors
A phase 1/2 trial of CM350 group1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.
Overview
A Study of CM350 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05263960 by Keymed Biosciences Co.Ltd, with 248 participants planned, started 2022-04-21 and due to reach its primary completion in 2027-04. Interventions recorded: CM350 group1, CM350 group2 and CM350 group3.
Similar pages
not linked directly; found by shared links- TrialStudy of CM518D1 in Patients With Advanced Solid Tumors
Shares Keymed Biosciences (KYM Biosciences), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.